Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

John Kelly

Physician Assistant, Medical Massapequa, NY Physician Assistant

NPI 1558704775 CMS profile 10525344

515 Broadway, Massapequa, NY 11758

Open in the dashboard

General payments

$19,220

856 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Kelly of Massapequa, NY is reported in the CMS Open Payments database as having received $19,220 across 856 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,921 192
2024 General $3,897 193
2023 General $3,201 155
2022 General $3,751 147
2021 General $4,451 169

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Kelly
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to John Kelly were reported at $3,921. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year John Kelly Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $4,451 $156 $41–$563 $132
2022 $3,751 $185 $55–$649 $149
2023 $3,201 $199 $58–$717 $160
2024 $3,897 $206 $62–$740 $164
2025 $3,921 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $2,830 115 payments
  2. AbbVie, Inc. $2,706 157 payments
  3. Amgen Inc. $2,606 55 payments
  4. GlaxoSmithKline, LLC. $1,740 74 payments
  5. Pfizer Inc. $1,166 61 payments
  6. Novo Nordisk Inc $1,136 67 payments
  7. Gilead Sciences, Inc. $1,056 48 payments
  8. Lilly USA, LLC $1,029 43 payments
  9. Abbott Laboratories $458 27 payments
  10. Merck Sharp & Dohme Corporation $456 23 payments
  11. Other $4,037 186 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $19,220 856 payments
Products named General payments · program years 2021–2025
  1. Repatha $1,777 40 payments
  2. TRELEGY ELLIPTA $1,653 69 payments
  3. UBRELVY $1,532 89 payments
  4. Otezla $1,260 39 payments
  5. FARXIGA $913 43 payments
  6. QULIPTA $892 65 payments
  7. AIRSUPRA $853 43 payments
  8. Ozempic $753 47 payments
  9. NURTEC ODT $722 36 payments
  10. MOUNJARO $673 25 payments
  11. Other $10,921 532 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 123 drugs

Part D claims

7,415

Median for Physician Assistant: 241

Drug cost

$1,073,676

Median for Physician Assistant: $4,110

Branded share of claims

21.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 141 $182,897
Eliquis Apixaban Brand 139 $140,260
Rybelsus Semaglutide Brand 58 $91,249
Ozempic Semaglutide Brand 69 $85,014
Jardiance Empagliflozin Brand 63 $82,089
Tresiba Flextouch U-200 Insulin Degludec Brand 35 $71,599
Otezla Apremilast Brand 12 $54,906
Januvia Sitagliptin Phosphate Brand 29 $41,235
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 43 $37,490
Mounjaro Tirzepatide Brand 34 $34,682

The 10 drugs with the highest cost, of 123 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$481 22 —
Repatha
$375 41 —
TRELEGY ELLIPTA
$204 43 —
UBRELVY
$186 — —
VRAYLAR
$180 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

856 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record